Mark Ruffalo

Showing 10331 articles
Business

Avnet's Soaring Stock: A Valuation Puzzle After a Stellar Run

Avnet's shares have surged over 28% this year, riding the wave of tech hardware demand cycles. But as the stock hovers around $63, a critical question emerges: is the rally justified by fundamentals, or has momentum outpaced value? A deep dive into the numbers reveals a starkly divided picture.

Business

CytomX Therapeutics Surges on Promising Early Colorectal Cancer Data, Analysts Bullish on Probody Platform

Shares of CytomX Therapeutics (CTMX) jumped over 14% this week after early-stage clinical data for its lead Probody candidate, varsetatug maseatecan, in metastatic colorectal cancer drew positive reactions from Wall Street. The move highlights growing confidence in the company's conditionally activated antibody platform, designed to target tumors more precisely while sparing healthy tissue.

Business

Sanmina Surpasses Revenue Expectations, Fueled by AI Infrastructure and ZT Systems Integration

Electronics manufacturer Sanmina reports stronger-than-anticipated revenue, driven by surging demand for AI infrastructure and high-performance networking systems. The company's recent acquisition of ZT Systems is poised to significantly bolster its position as new platforms enter volume production, with further growth expected from industrial, energy, and medical sectors later this year.